• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

测量囊性纤维化患者在肺部恶化期间和之后的健康相关生活质量的恢复情况。

Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis.

机构信息

Medical University of South Carolina, 96 Jonathan Lucas Street, 812-CSB, Charleston, SC 29425, USA.

Formerly of Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, USA.

出版信息

J Cyst Fibros. 2019 Sep;18(5):737-742. doi: 10.1016/j.jcf.2018.12.004. Epub 2018 Dec 23.

DOI:10.1016/j.jcf.2018.12.004
PMID:30587335
Abstract

BACKGROUND

We explored the time-dependent impact of pulmonary exacerbations (PEx) on health-related quality of life (HRQoL) using Cystic Fibrosis Questionnaire-Revised (CFQ-R) data from 2 large cystic fibrosis (CF) trials.

METHODS

This exploratory post-hoc analysis evaluated the impact of PEx on CFQ-R domains of functioning in 80 patients with CF (homozygous for F508del-CFTR), aged ≥14 years randomized to placebo in the TRAFFIC and TRANSPORT trials who experienced 1 PEx.

RESULTS

Scores on the CFQ-R were significantly lower within 1 week of PEx start in 8 out of 12 domains (Respiratory Symptoms, Physical Functioning, Emotional Functioning, Health Perceptions, Role Functioning, Social Functioning, Eating, and Vitality). Patients whose PEx was treated with hospitalization or intravenous antibiotics had greater reductions in some domains of HRQoL compared with those treated with oral antibiotics. In the immediate weeks post-PEx, improvement was seen on Emotional Functioning, Respiratory Symptoms, and Health Perceptions, while further decline was seen for Eating, Physical Functioning, Role Functioning, Vitality, and Weight. For some measures (Physical Functioning, Vitality), full recovery to pre-PEx levels took several weeks.

CONCLUSIONS

Pulmonary exacerbations have significant effects on multiple domains of HRQoL, and recovery across multiple domains post-PEx can take several weeks. These findings provide insight into the impact of PEx on patient HRQoL and recovery post-PEx.

CLINICAL TRIAL REGISTRATION

ClinicalTrials.gov identifiers, NCT01807923 and NCT01807949.

摘要

背景

我们利用来自两项大型囊性纤维化(CF)试验的囊性纤维化问卷修订版(CFQ-R)数据,探索了肺部恶化(PEx)对健康相关生活质量(HRQoL)的时间依赖性影响。

方法

这项探索性的事后分析评估了 80 名携带 F508del-CFTR 纯合子 CF 患者(年龄≥14 岁)在 TRAFFIC 和 TRANSPORT 试验中接受安慰剂治疗,经历了 1 次 PEx 后对 CFQ-R 功能领域的影响。

结果

在 12 个领域中的 8 个领域中,在 PEx 开始后 1 周内,CFQ-R 的评分明显降低(呼吸道症状、身体机能、情绪功能、健康感知、角色功能、社会功能、饮食和活力)。与接受口服抗生素治疗的患者相比,接受住院或静脉用抗生素治疗的患者在某些 HRQoL 领域的评分下降幅度更大。在 PEx 后立即的几周内,情绪功能、呼吸道症状和健康感知有所改善,而饮食、身体机能、角色功能、活力和体重则进一步下降。对于某些指标(身体机能、活力),需要几周时间才能完全恢复到 PEx 前的水平。

结论

肺部恶化对 HRQoL 的多个领域有显著影响,而 PEx 后多个领域的恢复可能需要数周时间。这些发现为了解 PEx 对患者 HRQoL 的影响和 PEx 后恢复情况提供了深入的见解。

临床试验注册

ClinicalTrials.gov 标识符,NCT01807923 和 NCT01807949。

相似文献

1
Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis.测量囊性纤维化患者在肺部恶化期间和之后的健康相关生活质量的恢复情况。
J Cyst Fibros. 2019 Sep;18(5):737-742. doi: 10.1016/j.jcf.2018.12.004. Epub 2018 Dec 23.
2
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV.无论初始 FEV 变化如何,Lumacaftor/Ivacaftor 均可减少患者的肺部恶化。
J Cyst Fibros. 2019 Jan;18(1):94-101. doi: 10.1016/j.jcf.2018.07.011. Epub 2018 Aug 23.
3
Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study.依伐卡托特治疗囊性纤维化伴 G551D 突变患者的患者报告结局:一项横断面研究的结果。
BMC Pulm Med. 2019 Aug 13;19(1):146. doi: 10.1186/s12890-019-0887-6.
4
Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR.Lumacaftor/ivacaftor 治疗 F508del-CFTR 纯合子的囊性纤维化和晚期肺病患者。
J Cyst Fibros. 2018 Mar;17(2):228-235. doi: 10.1016/j.jcf.2017.09.012. Epub 2017 Nov 8.
5
Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial.依伐卡托治疗囊性纤维化和G551D-CFTR突变患者的疗效:STRIVE随机对照试验中的患者报告结局
Health Qual Life Outcomes. 2015 Jul 2;13:93. doi: 10.1186/s12955-015-0293-6.
6
Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.鲁马卡托/依伐卡托,一种用于治疗F580del囊性纤维化跨膜传导调节因子(CFTR)突变纯合子的囊性纤维化患者的新型药物。
Expert Rev Clin Pharmacol. 2017 Oct;10(10):1055-1072. doi: 10.1080/17512433.2017.1378094. Epub 2017 Sep 22.
7
Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor.一名携带F508del/F508del囊性纤维化基因型且肺部破坏已进展的患者在使用鲁马卡托/依伐卡托治疗后成功妊娠。
Klin Padiatr. 2019 Sep;231(5):271-273. doi: 10.1055/a-0973-8565. Epub 2019 Aug 13.
8
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.囊性纤维化的增效剂(针对III类和IV类突变的特定疗法)。
Cochrane Database Syst Rev. 2015 Mar 26(3):CD009841. doi: 10.1002/14651858.CD009841.pub2.
9
Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States.芦山卡福特和依伐卡福特联合治疗美国囊性纤维化患者的成本效益分析。
Orphanet J Rare Dis. 2018 Sep 29;13(1):172. doi: 10.1186/s13023-018-0914-3.
10
Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.Lumacaftor/Ivacaftor:囊性纤维化治疗药物。
Drugs. 2016 Aug;76(12):1191-201. doi: 10.1007/s40265-016-0611-2.

引用本文的文献

1
Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.依伐卡托-替扎卡托-艾列卡托、替扎卡托-依伐卡托和鲁玛卡托-依伐卡托治疗囊性纤维化:系统评价与经济学评估
Health Technol Assess. 2025 May;29(19):1-111. doi: 10.3310/CPLD8546.
2
Tools used to measure quality of life in adults with cystic fibrosis- a systematic review.用于测量成年囊性纤维化患者生活质量的工具——一项系统综述。
Health Qual Life Outcomes. 2025 Feb 4;23(1):10. doi: 10.1186/s12955-025-02338-2.
3
Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators.
囊性纤维化跨膜传导调节因子(CFTR)调节剂时代的变应性支气管肺曲霉病(ABPA)
J Fungi (Basel). 2024 Sep 18;10(9):656. doi: 10.3390/jof10090656.
4
Polish Cystic Fibrosis Patients' Health-Related Quality of Life and Its Influencing Factors: A Cross-Sectional, Single-Centre Study.波兰囊性纤维化患者的健康相关生活质量及其影响因素:一项横断面单中心研究
Healthcare (Basel). 2024 Jun 12;12(12):1183. doi: 10.3390/healthcare12121183.
5
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对携带 II 类 CFTR 基因突变(最常见的是 F508del)的囊性纤维化患者的校正治疗(有或没有增效剂)。
Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD010966. doi: 10.1002/14651858.CD010966.pub4.
6
Long-Term Follow-Up of Health-Related Quality of Life and Short-Term Intervention with CFTR Modulator Therapy in Adults with Cystic Fibrosis: Evaluation of Changes over Several Years with or without 33 Weeks of CFTR Modulator Therapy.囊性纤维化成年患者健康相关生活质量的长期随访及CFTR调节剂疗法的短期干预:评估接受或未接受33周CFTR调节剂疗法情况下数年的变化
Healthcare (Basel). 2023 Oct 31;11(21):2873. doi: 10.3390/healthcare11212873.
7
Telemedicine and Its Application in Cystic Fibrosis.远程医疗及其在囊性纤维化中的应用。
J Pers Med. 2023 Jun 25;13(7):1041. doi: 10.3390/jpm13071041.
8
Pulmonary bacteriophage and cystic fibrosis airway mucus: friends or foes?肺部噬菌体与囊性纤维化气道黏液:是友还是敌?
Front Med (Lausanne). 2023 May 17;10:1088494. doi: 10.3389/fmed.2023.1088494. eCollection 2023.
9
Antibiotic Therapy for Pulmonary Exacerbations in Cystic Fibrosis-A Single-Centre Prospective Observational Study.囊性纤维化肺部加重期的抗生素治疗——一项单中心前瞻性观察研究
Antibiotics (Basel). 2023 Apr 9;12(4):734. doi: 10.3390/antibiotics12040734.
10
The Clinical Association between and Respiratory Outcomes in Adolescents and Adults with Cystic Fibrosis.囊性纤维化青少年和成人中 与呼吸系统结局的临床关联。
Ann Am Thorac Soc. 2023 Jul;20(7):984-992. doi: 10.1513/AnnalsATS.202210-852OC.